Relay Therapeutics, Inc. (RLAY)

Every figure this model derived for RLAY, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 410,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 121,189,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 928,082,000 AssetsCurrent 2026-06-30
current liabilities 50,804,000 LiabilitiesCurrent 2026-06-30
equity 890,009,000 StockholdersEquity 2026-06-30
ocf -212,205,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 10,350,000 Revenues 2026-06-30
sbc 48,310,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RLAY on one particular measure came for.

RatioValue
current ratio18.27
current ratio reported18.27
deferred revenue growth-79.95
dilution pct20.12
fcf margin-2054.25
growth cv2.25
revenue growth23.86
revenue growth per share3.12
roic-31.9
rule of 40-2975.51
sbc pct revenue466.76

What to be careful about

What this model itself distrusts about RLAY's figures. Written by the derivation as it ran, not added afterwards.